Japanese Journal of Cancer and Chemotherapy最新文献_第9页

[Gut Microbiota as a Potential Biomarker for Immune Checkpoint Inhibitors]. [肠道微生物群作为免疫检查点抑制剂的潜在生物标记物]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Yuki Ozaki, Yoshiki Suzuki, Hiroyuki Suzuki

{"title":"[Gut Microbiota as a Potential Biomarker for Immune Checkpoint Inhibitors].","authors":"Yuki Ozaki, Yoshiki Suzuki, Hiroyuki Suzuki","doi":"","DOIUrl":"","url":null,"abstract":"Immune checkpoint inhibitors(ICIs)currently play a predominant role in the standard treatment of non-small cell lung cancer(NSCLC)across all stages. While PD-L1 positivity has traditionally been used as the sole effective biomarker, evidence suggests that certain efficacy exists even in PD-L1-negative lung cancers. Various investigations have been conducted to identify biomarkers predicting the therapeutic efficacy of ICIs, focusing on both tumor-local and host-related factors. Among indicators reflecting the host status, the gut microbiota has garnered attention, with its composition and diversity potentially influencing the efficacy of ICI therapy. The presence of specific gut microbiota has been frequently reported to enhance the effectiveness of ICI treatment. Furthermore, the use of antibiotics may diminish the effects of ICIs, while fecal microbiota transplantation has shown potential to enhance ICI therapy. In our department, analysis of the gut microbiota in patients receiving anti-PD-1 antibody treatment has been conducted, yielding promising results through the identification of specific bacterial species and the search for these species using real-time PCR, suggesting avenues for further research. Recently, attention has also been drawn to the lung microbiota and tumor microbiota in the context of lung cancer, with reports suggesting that increased diversity in these microbial communities may correlate with the efficacy of ICI therapy. However, none of these findings alone provide sufficient evidence as standalone biomarkers, necessitating future research to advance from both the host environment, including the gut microbiota, and the microenvironment of the tumor site, such as the lung and tumor microbiota.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 9","pages":"862-864"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Safety and Efficacy of Nivolumab plus Ipilimumab Therapy-Our Real World Experience]. [Nivolumab联合Ipilimumab疗法的安全性和有效性--我们的真实体验]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi, Junichiro Itani, Daiki Sone, Makoto Nakae, Kenji Morimoto, Satoru Okada, Takeshi Yamada, Atsuko Fujihara, Atsushi Shiozaki, Hitoshi Fujiwara, Norito Katoh, Koichi Takayama, Yoshito Itoh

{"title":"[Safety and Efficacy of Nivolumab plus Ipilimumab Therapy-Our Real World Experience].","authors":"Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi, Junichiro Itani, Daiki Sone, Makoto Nakae, Kenji Morimoto, Satoru Okada, Takeshi Yamada, Atsuko Fujihara, Atsushi Shiozaki, Hitoshi Fujiwara, Norito Katoh, Koichi Takayama, Yoshito Itoh","doi":"","DOIUrl":"","url":null,"abstract":"In Japan, cancer immunotherapy using immune checkpoint inhibitors(ICIs)has become a new treatment modality in cancer chemotherapy in the 2010s, and is now widely approved for many types of cancer. Today, combination cancer immunotherapy utilizing ICIs is being developed, with many cancer types. The first approved ICI combination in Japan consists of nivolumab, an anti-PD-1 antibody, and ipilimumab, an anti-CTLA-4 antibody. In the combination therapy, ipilimumab is administered at different doses, intervals, and frequencies depending on the cancer type. ICI combination therapy has been reported to be more effective than ICI monotherapy, but also be associated with more severe adverse events. Therefore, optimal dosing strategies for ipilimumab were explored considering both treatment efficacy and adverse event profiles. In the study of 64 cases with multiple cancer, higher efficacy of ICI combined therapy was expected in cases with irAEs, and there were cases with long-lasting efficacy even after early discontinuation of ipilimumab due to irAEs. And the high dose(3 mg/kg)of ipilimumab was suggested to be an independent risk factor for CTCAE Grade 3 or higher for severe irAEs.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 9","pages":"879-884"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ⅱ. Advancement in Chemotherapy for Unresectable or Recurrent Esophageal Cancer]. [Ⅱ.无法切除或复发食管癌化疗的进展]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Takahiro Tsushima

引用次数: 0

[A Retrospective Study on the Current Status of Adjustment of Transition to the Place of Care for Patients with Terminal Cancer and Factors Leading to the Discontinuation of Such Adjustment]. [癌症晚期患者过渡到护理场所的调整现状及导致停止调整的因素的回顾性研究]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Chikako Sekine, Tomomi Hasegawa, Sayo Aiki, Keiji Tatsumi, Motohiro Hirao

{"title":"[A Retrospective Study on the Current Status of Adjustment of Transition to the Place of Care for Patients with Terminal Cancer and Factors Leading to the Discontinuation of Such Adjustment].","authors":"Chikako Sekine, Tomomi Hasegawa, Sayo Aiki, Keiji Tatsumi, Motohiro Hirao","doi":"","DOIUrl":"","url":null,"abstract":"Background: Transitioning patients with cancer to end-of-life care settings poses psychological and operational challenges for patients, families, medical personnel, and collaborating medical institutions. However, such transitions may not always occur due to patient's deteriorating condition or death. Predicting the feasibility of these transitions is crucial for effective use of medical resources and effectuating end-of-life wishes. However, there are no reports examining the factors contributing to the discontinuation of adjustment.Methods: We conducted a retrospective analysis of 235 patients with terminal cancer at our hospital, assessing estimated prognosis, preferred place of care, number of days of MSW intervention, number of days survived post-intervention, and completion/discontinuation of adjustment. Medical social workers(hereafter, MSW)facilitated patient transitions in FY2021. We calculated odds ratios associated with adjustment discontinuation and estimated prognosis.Results: On average, patients received 22.9 days of intervention. Those patients completing the transition spent an average of 20.3 days at home and 28.6 days in a facility(p<0.001), with home adjustment being significantly shorter. Patients with estimated prognosis of less than 1 month were 7.1 times more likely to adjustment discontinuation than those with an estimated prognosis of 1 month or more.Conclusion: Patients with estimated prognosis of less than 1 month were less likely to complete the adjustment. Considering the psychological and operational challenges for patients, families, and medical personnel, end-of-life care in cancer treatment hospitals must be considered. More information on the factors leading to the discontinuation of adjustments is expected to be accumulated in the future.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 9","pages":"919-923"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Identification of Predictive Biomarkers for Immune Checkpoint Inhibitors by Immunogenomics]. [通过免疫基因组学鉴定免疫检查点抑制剂的预测性生物标记物]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Taigo Kato

引用次数: 0

[Shared Decision-Making in Cancer Care of Japan]. [日本癌症治疗中的共同决策]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Etsuko Aruga

引用次数: 0

[A Case of a Colorectal Villous Tumor with Electrolyte Depletion Syndrome Treated with Robot-Assisted Surgery]. [机器人辅助手术治疗伴有电解质耗竭综合征的结直肠绒毛膜肿瘤病例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Shuhei Narita, Tsuyoshi Ohtani, Yuko Takehara, Tetsuya Katayama, Kaori Nitta, Eiki Miyake, Tomokazu Fuji, Masanobu Maruyama, Yoshihiro Akazai, Soichiro Nose

{"title":"[A Case of a Colorectal Villous Tumor with Electrolyte Depletion Syndrome Treated with Robot-Assisted Surgery].","authors":"Shuhei Narita, Tsuyoshi Ohtani, Yuko Takehara, Tetsuya Katayama, Kaori Nitta, Eiki Miyake, Tomokazu Fuji, Masanobu Maruyama, Yoshihiro Akazai, Soichiro Nose","doi":"","DOIUrl":"","url":null,"abstract":"Colorectal villous tumors secrete large amounts of mucus that can cause electrolyte abnormalities and dehydration, a condition known as electrolyte depletion syndrome. A woman in her 70s, who had been underweight for 10 years with a body mass index(BMI)of 16, was admitted to our hospital with electrolyte abnormalities, renal disorders, and rectal tumors. The electrolyte abnormalities and renal disorders were corrected relatively quickly with supplemental fluid therapy. Notably, 1,000 g of mucus stool per day was observed; subsequently, a lower gastrointestinal endoscopy revealed a circumferential villous tumor in the Rb of the rectum, which was biopsied and diagnosed as rectal cancer and electrolyte depletion syndrome. The patient was temporarily discharged from the hospital; however, several days later, the electrolyte abnormalities and renal disorders recurred. The patient was readmitted to the hospital and underwent robot-assisted Hartmann's surgery after improvement of the general condition of the patient. Postoperative pathology revealed papillary adenocarcinoma with SM depth, and the patient progressed without recurrence or relapse of electrolyte depletion syndrome.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 9","pages":"947-949"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Combined Small Cell Lung Cancer Presenting as Malignant Psoas Syndrome]. [一例合并小细胞肺癌并表现为恶性腰肌综合征的病例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Yasuki Hachisuka, Masashi Uomoto

引用次数: 0

[A Case of Drug-Induced Lung Injury That Developed the Day after Abemaciclib Treatment for Advanced Breast Cancer]. [晚期乳腺癌 Abemaciclib 治疗后第二天出现的药物诱发肺损伤病例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Mikiko Kai, Yumiko Taki, Akiko Ikeda, Tatsuya Igarashi, Satoshi Hasegawa

引用次数: 0

[PD-L1-Expressing Cancer-Associated Fibroblasts Have the Potential of a Biomarker for Immune Checkpoint Inhibitors]. [表达 PD-L1 的癌症相关成纤维细胞有望成为免疫检查点抑制剂的生物标记物］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Kento Kawasaki, Kazuhiro Noma, Toshiyoshi Fujiwara

引用次数: 0